期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 169, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2023.115897
关键词
Polycomb repressor complex; Epigenetic modification; Tumorigenesis; Cancer progression; Therapeutic target
The Polycomb Repressor Complex (PRC) plays a crucial role in gene regulation and its interaction with cellular signaling pathways sheds light on the complexity of cancer. Dysregulation of the PRC complex is significant in various tumors and understanding the underlying mechanisms driving cancer progression is important. The development of therapeutic strategies targeting PRC complexes, particularly EZH2 inhibitors, has made significant advancements and combination therapies may enhance targeted treatments efficacy.
The Polycomb Repressor Complex (PRC) plays a pivotal role in gene regulation during development and disease, with dysregulation contributing significantly to various human cancers. The intricate interplay between PRC and cellular signaling pathways sheds light on cancer complexity. PRC presents promising therapeutic opportunities, with inhibitors undergoing rigorous evaluation in preclinical and clinical studies. In this review, we emphasize the critical role of PRC complex in gene regulation, particularly PcG proteins mediated chromatin compaction through phase separation. We also highlight the pathological implications of PRC complex dysregulation in various tumors, elucidating underlying mechanisms driving cancer progression. The burgeoning field of thera-peutic strategies targeting PRC complexes, notably EZH2 inhibitors, has advanced significantly. However, we explore the need for combination therapies to enhance PRC targeted treatments efficacy, providing a glimpse into the future of cancer therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据